The molecular hallmarks of primary and secondary vitreoretinal lymphoma

Standard

The molecular hallmarks of primary and secondary vitreoretinal lymphoma. / Bonzheim, Irina; Sander, Philip; Salmeron-Villalobos, Julia; Süsskind, Daniela; Szurman, Peter; Gekeler, Florian; Spitzer, Martin S; Steinhilber, Julia; Kohler, Esther; Büssgen, Melanie; Schittenhelm, Jens; Salaverria, Itziar; Campo, Elias; Coupland, Sarah E; Quintanilla-Martinez, Leticia; Fend, Falko.

in: BLOOD ADV, Jahrgang 6, Nr. 5, 08.03.2022, S. 1598-1607.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Bonzheim, I, Sander, P, Salmeron-Villalobos, J, Süsskind, D, Szurman, P, Gekeler, F, Spitzer, MS, Steinhilber, J, Kohler, E, Büssgen, M, Schittenhelm, J, Salaverria, I, Campo, E, Coupland, SE, Quintanilla-Martinez, L & Fend, F 2022, 'The molecular hallmarks of primary and secondary vitreoretinal lymphoma', BLOOD ADV, Jg. 6, Nr. 5, S. 1598-1607. https://doi.org/10.1182/bloodadvances.2021004212

APA

Bonzheim, I., Sander, P., Salmeron-Villalobos, J., Süsskind, D., Szurman, P., Gekeler, F., Spitzer, M. S., Steinhilber, J., Kohler, E., Büssgen, M., Schittenhelm, J., Salaverria, I., Campo, E., Coupland, S. E., Quintanilla-Martinez, L., & Fend, F. (2022). The molecular hallmarks of primary and secondary vitreoretinal lymphoma. BLOOD ADV, 6(5), 1598-1607. https://doi.org/10.1182/bloodadvances.2021004212

Vancouver

Bonzheim I, Sander P, Salmeron-Villalobos J, Süsskind D, Szurman P, Gekeler F et al. The molecular hallmarks of primary and secondary vitreoretinal lymphoma. BLOOD ADV. 2022 Mär 8;6(5):1598-1607. https://doi.org/10.1182/bloodadvances.2021004212

Bibtex

@article{511384b84a3b4f23947837d4281fb152,
title = "The molecular hallmarks of primary and secondary vitreoretinal lymphoma",
abstract = "Vitreoretinal lymphoma (VRL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) considered a variant of primary central nervous system lymphoma (PCNSL). The diagnosis of VRL requires examination of vitreous fluid, but cytologic differentiation from uveitis remains difficult. Because of its rarity and the difficulty in obtaining diagnostic material, little is known about the genetic profile of VRL. The purpose of our study was to investigate the mutational profile of a large series of primary and secondary VRL. Targeted next-generation sequencing using a custom panel containing the most frequent mutations in PCNSL was performed on 34 vitrectomy samples from 31 patients with VRL and negative controls with uveitis. In a subset of cases, genome-wide copy number alterations (CNAs) were assessed using the OncoScan platform. Mutations in MYD88 (74%), PIM1 (71%), CD79B (55%), IGLL5 (52%), TBL1XR1 (48%), ETV6 (45%), and 9p21/CDKN2A deletions (75%) were the most common alterations, with similar frequencies in primary (n = 16), synchronous (n = 3), or secondary (n = 12) VRL. This mutational spectrum is similar to MYD88mut/CD79Bmut (MCD or cluster 5) DLBCL with activation of Toll-like and B-cell receptor pathways and CDKN2A loss, confirming their close relationship. OncoScan analysis demonstrated a high number of CNAs (mean 18.6 per case). Negative controls lacked mutations or CNAs. Using cell-free DNA of vitreous fluid supernatant, mutations present in cellular DNA were reliably detected in all cases examined. Mutational analysis is a highly sensitive and specific tool for the diagnosis of VRL and can also be applied successfully to cell-free DNA derived from the vitreous.",
author = "Irina Bonzheim and Philip Sander and Julia Salmeron-Villalobos and Daniela S{\"u}sskind and Peter Szurman and Florian Gekeler and Spitzer, {Martin S} and Julia Steinhilber and Esther Kohler and Melanie B{\"u}ssgen and Jens Schittenhelm and Itziar Salaverria and Elias Campo and Coupland, {Sarah E} and Leticia Quintanilla-Martinez and Falko Fend",
note = "Copyright {\textcopyright} 2021 American Society of Hematology.",
year = "2022",
month = mar,
day = "8",
doi = "10.1182/bloodadvances.2021004212",
language = "English",
volume = "6",
pages = "1598--1607",
journal = "BLOOD ADV",
issn = "2473-9529",
publisher = "Elsevier BV",
number = "5",

}

RIS

TY - JOUR

T1 - The molecular hallmarks of primary and secondary vitreoretinal lymphoma

AU - Bonzheim, Irina

AU - Sander, Philip

AU - Salmeron-Villalobos, Julia

AU - Süsskind, Daniela

AU - Szurman, Peter

AU - Gekeler, Florian

AU - Spitzer, Martin S

AU - Steinhilber, Julia

AU - Kohler, Esther

AU - Büssgen, Melanie

AU - Schittenhelm, Jens

AU - Salaverria, Itziar

AU - Campo, Elias

AU - Coupland, Sarah E

AU - Quintanilla-Martinez, Leticia

AU - Fend, Falko

N1 - Copyright © 2021 American Society of Hematology.

PY - 2022/3/8

Y1 - 2022/3/8

N2 - Vitreoretinal lymphoma (VRL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) considered a variant of primary central nervous system lymphoma (PCNSL). The diagnosis of VRL requires examination of vitreous fluid, but cytologic differentiation from uveitis remains difficult. Because of its rarity and the difficulty in obtaining diagnostic material, little is known about the genetic profile of VRL. The purpose of our study was to investigate the mutational profile of a large series of primary and secondary VRL. Targeted next-generation sequencing using a custom panel containing the most frequent mutations in PCNSL was performed on 34 vitrectomy samples from 31 patients with VRL and negative controls with uveitis. In a subset of cases, genome-wide copy number alterations (CNAs) were assessed using the OncoScan platform. Mutations in MYD88 (74%), PIM1 (71%), CD79B (55%), IGLL5 (52%), TBL1XR1 (48%), ETV6 (45%), and 9p21/CDKN2A deletions (75%) were the most common alterations, with similar frequencies in primary (n = 16), synchronous (n = 3), or secondary (n = 12) VRL. This mutational spectrum is similar to MYD88mut/CD79Bmut (MCD or cluster 5) DLBCL with activation of Toll-like and B-cell receptor pathways and CDKN2A loss, confirming their close relationship. OncoScan analysis demonstrated a high number of CNAs (mean 18.6 per case). Negative controls lacked mutations or CNAs. Using cell-free DNA of vitreous fluid supernatant, mutations present in cellular DNA were reliably detected in all cases examined. Mutational analysis is a highly sensitive and specific tool for the diagnosis of VRL and can also be applied successfully to cell-free DNA derived from the vitreous.

AB - Vitreoretinal lymphoma (VRL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) considered a variant of primary central nervous system lymphoma (PCNSL). The diagnosis of VRL requires examination of vitreous fluid, but cytologic differentiation from uveitis remains difficult. Because of its rarity and the difficulty in obtaining diagnostic material, little is known about the genetic profile of VRL. The purpose of our study was to investigate the mutational profile of a large series of primary and secondary VRL. Targeted next-generation sequencing using a custom panel containing the most frequent mutations in PCNSL was performed on 34 vitrectomy samples from 31 patients with VRL and negative controls with uveitis. In a subset of cases, genome-wide copy number alterations (CNAs) were assessed using the OncoScan platform. Mutations in MYD88 (74%), PIM1 (71%), CD79B (55%), IGLL5 (52%), TBL1XR1 (48%), ETV6 (45%), and 9p21/CDKN2A deletions (75%) were the most common alterations, with similar frequencies in primary (n = 16), synchronous (n = 3), or secondary (n = 12) VRL. This mutational spectrum is similar to MYD88mut/CD79Bmut (MCD or cluster 5) DLBCL with activation of Toll-like and B-cell receptor pathways and CDKN2A loss, confirming their close relationship. OncoScan analysis demonstrated a high number of CNAs (mean 18.6 per case). Negative controls lacked mutations or CNAs. Using cell-free DNA of vitreous fluid supernatant, mutations present in cellular DNA were reliably detected in all cases examined. Mutational analysis is a highly sensitive and specific tool for the diagnosis of VRL and can also be applied successfully to cell-free DNA derived from the vitreous.

U2 - 10.1182/bloodadvances.2021004212

DO - 10.1182/bloodadvances.2021004212

M3 - SCORING: Journal article

C2 - 34448823

VL - 6

SP - 1598

EP - 1607

JO - BLOOD ADV

JF - BLOOD ADV

SN - 2473-9529

IS - 5

ER -